Chemotherapeutic Drug Carrier Reduces Tissue Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic drugs often have high toxicity to healthy tissues, leading to dose reduction or discontinuation, and many are rejected by regulatory agencies due to excessive toxicity despite efficacy, highlighting the need for therapies with decreased toxicity that can efficiently target tumor cells.
Innovation Solution
Combining chemotherapeutic drugs with a biocompatible protein carrier and antibodies or aptamers that target tumor cells, forming a complex to enhance drug delivery and reduce side effects, thereby increasing the therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If chemotherapeutic drugs are administered alone, then they can reach tumor cells, but they cause high toxicity to healthy tissues
Solution Approach 1:
The patent uses a protein carrier (such as albumin) as an intermediary to transport the chemotherapeutic drug. The carrier binds to the drug and delivers it to tumor cells through specific recognition mechanisms, reducing direct contact between the drug and healthy tissues. This mediator approach allows the drug to reach its target while minimizing off-target toxicity effects.
Solution Approach 2:
The patent extracts the toxic chemotherapeutic agent from its conventional free-state administration and incorporates it into a specialized delivery system. By taking the drug out of direct circulation and embedding it within a targeted carrier system, the patent separates the drug's anticancer efficacy from its harmful toxicity to healthy tissues.
2Object-affected harmful factors
If the dose of chemotherapeutic drugs is reduced to decrease toxicity, then side effects are reduced, but treatment efficacy decreases
Solution Approach 1:
The patent applies local quality by creating a delivery system with different properties at different locations: the carrier exhibits high affinity and specificity at the tumor site (local target), while showing minimal interaction with healthy tissues. This spatial differentiation of binding properties allows concentrated drug delivery to tumors without proportionally increasing systemic toxicity.
3Object-affected harmful factors
If targeted delivery using antibodies is implemented, then drug specificity to tumor cells improves, but the system complexity increases
Solution Approach 1:
The patent employs protein carriers that perform multiple functions simultaneously: they serve as drug carriers, provide targeting capability through albumin recognition by tumor cells, and act as biocompatible vehicles. This multi-functionality reduces the need for separate targeting components, thereby managing system complexity while maintaining high drug specificity.
4Reliability
If chemotherapeutic drugs are used to treat cancer, then tumor cells are attacked, but the therapeutic index is unacceptable due to excessive toxicity
Solution Approach 1:
The patent converts the inherently toxic nature of chemotherapeutic drugs into a benefit by using the toxicity selectively against tumor cells. The protein carrier system ensures that the harmful drug is concentrated at the tumor site while protecting healthy tissues, thereby transforming a harmful substance into a targeted therapeutic weapon that benefits the patient.
Data Source
AI summary
This disclosure relates to methods for improving the therapeutic index of a chemotherapeutic drug in the treatment of patients afflicted with cancer, by reducing chemotherapy-related toxicity to a level that allows the chemotherapeutic drug to be used in humans.